Thank you for checking on Entheon. We are glad to have you here!
"Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada."
Official publications released at Newsfile Corp.
Please enter your information to receive our investor package or reach out to us directly using the information below.
Joseph Cullen
Investor Relations
ir@entheonbiomedical.com
+1 (778) 919-8615